The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat

l-DOPA continues to be the primary treatment for patients with Parkinson's disease; however, the benefits of long-term treatment are often accompanied by debilitating side effects known as dyskinesias. In recent years, several 5-HT1A receptor agonists have been found to reduce dyskinesia in clinical and experimental models of PD. The purported sigma-1 antagonist, BMY-14802 has been previously demonstrated to reduce l-DOPA induced dyskinesia in a 5-HT1A receptor dependent manner. In the present study, we extend these findings by examining the anti-dyskinetic potential of BMY-14802 against l-DOPA, the D-1 receptor agonist SKF81297 and the D-2 receptor agonist, quinpirole, in the hemi-parkinsonian rat model. In addition, the receptor specificity of BMY-14802's effects was evaluated using WAY-100635, a 5-HT1A receptor antagonist. Results confirmed the dose-dependent (20 > 10 > 5 mg/kg) anti-dyskinetic effects of BMY-14802 against l-DOPA with preservation of anti-parkinsonian efficacy at 10 mg/kg. BMY-14802 at 10 and 20 mg/kg also reduced dyskinesia induced by both D-1 and D-2 receptor agonists. Additionally, BMY-14802's anti-dyskinetic effects against l-DOPA, but not SKF81297 or quinpirole, were reversed by WAY-100635 (0.5 mg/kg). Collectively, these findings demonstrate that BMY-14802 provides anti-dyskinetic relief against l-DOPA and direct DA agonist in a preclinical model of PD, acting via multiple receptor systems and supports the utility of such compounds for the improved treatment of PD.